About the program

Program publication date: May 2022

Breast cancer is the leading cause of cancer-related deaths for women worldwide

Despite advances in diagnostic tools and therapies available, approximately 1 in 6 patients diagnosed with HR+/HER2- early breast cancer will experience disease recurrence within 5 years of treatment.

This expert-led program aims to improve the individualized management of HR+/HER2- early breast cancer through education on recurrence risk classification, current evidence-based guidelines, and new and emerging therapies.

There will also be guidance on integrating shared decision making into your practice drawing on insights from a patient on how best to communicate.

Latest Content

Sign up for new content alerts

Enter your email address below and we'll contact you as soon as new content is launched!

HCP confirmation(Required)
Privacy Policy Acceptance(Required)
This field is for validation purposes and should be left unchanged.